SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs shares fell despite a third-quarter earnings beat and a new buyback, as traders focused on the narrowed full-year profit outlook and unchanged midpoint. The reaction is split between dip buyers citing cash generation and repurchases, and bears who see the outlook and softer sales as outweighing those positives.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as traders watch for Q3 results to confirm continued growth in high-margin ASCENIV amid weakness in BIVIGAM, with the recent move around its 200-day average adding to the recovery discussion. Bulls point to ASCENIV and share repurchases, while skeptics cite uncertain growth and lingering concerns from the Culper short report and related litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HIMS Stock Gains As Company Enters German Men’s Weight Market As Investors Watch US Peptide Compounding Policy

Equity

Hims is introducing online weight-management care for men in Germany, beginning with private consultations that can lead to prescriptions from EU-licensed clinicians. 


Noteworthy ETF Outflows: IJH, OKTA, NVT, MTSI

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Mid-Cap ETF (Symbol: IJH) where we have detected an approximate $135.1 million dollar outflow -- that's a 0.1% decrease week ov...

GME Rises After Hours As Ryan Cohen Buys Another 844K Shares Worth Near $23M

Cohen acquired 67,130 shares at $26.75 apiece and another 777,000 shares at $27, according to a filing with the Securities and Exchange Commission.


IJH, TWLO, OKTA, FTI: ETF Outflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Mid-Cap ETF (Symbol: IJH) where we have detected an approximate $967.1 million dollar outflow -- that's a 0.8% decrease week ov...

Should iShares Core S&P Mid-Cap ETF (IJH) Be on Your Investing Radar?

GME Pops 3% After the Bell As CEO Buys $26M Worth of Shares   

According to a filing with the Securities and Exchange Commission on Monday, Cohen bought 1.15 million GME shares in multiple transactions priced between $22.76 and $23.02 for roughly $26.4 million.


Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’ 

Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.


CELH Ticks Up After-Hours As Director DeSantis Follows CEO With $1M Buy

DeSantis, an independent director and son of late Celsius backer Carl DeSantis, purchased 20,000 shares on Monday at a weighted average of $27.65 and another 16,000 on Tuesday at $27.95.


ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?

ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July. 


EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread. 

iShares Trust - iShares Core S&P Mid-Cap ETF

Bearish Sentiment

<ul class="summary-bullets"><li>The new launch builds on the company’s earlier efforts at expanding in Europe, including the acquisition of UK-based health firm Zava.&nbsp;</li><li>HIMS investors are also watching for potential shifts in U.S. peptide compounding rules.</li><li>Hims &amp; Hers has also faced setbacks this year, including an FTC lawsuit filed in late July alleging deceptive privacy practices.</li></ul>Shares of Hims &amp; Hers Health (HIMS) rose 6% on Tuesday, as the company launched in Germany with a new men’s weight-management offering, adding another layer of international expansion.Hims is introducing online weight-management care for men in Germany, beginning with private consultations that can lead to prescriptions from EU-licensed clinicians, along with continued support. Patients better suited to in-person care will be directed to local providers, the company said.Nearly one in five German adults has obesity and more than six in ten men are overweight, Hims said. Statutory insurance generally does not cover weight loss medications, so individuals often pay themselves. Surveys cited by the company indicate that more than 75% of adults who attempted weight management did so with little professional guidance, and 42% preferred not to discuss the topic with a general practitioner.The new launch builds on the company’s earlier efforts at expanding in Europe, including the acquisition of UK-based health firm Zava, aimed at expanding the company’s footprint in the region.<h2 class="st-heading-2">US Peptide Compounding Policy Stays In Focus For HIMS</h2>The announcement also comes as investors watch potential shifts in U.S. peptide compounding rules.Hims has already prepared for a potential approval by securing a California peptide facility and testing ingredients, while signaling interest in offering items such as sermorelin, glutathione, and NAD+ depending on final regulatory outcomes.In mid-October, the Department of Health and Human Services advanced an interim policy on certain compounded peptides. This helped lift Hims shares after a July advisory committee reviewed several peptides and voted to recommend that six of seven, including BPC-157, be allowed for pharmacy compounding. The recommendations are not final; the FDA still has to decide and complete formal rulemaking.HIMS, however, has also faced setbacks this year, including an FTC lawsuit filed in late July alleging deceptive privacy practices involving data sharing with advertising platforms and misleading billing or cancellation practices. The company transitioned from offering compounded GLP-1s to branded versions earlier this year, pressuring margins despite subscriber growth.<h2 class="st-heading-2">How Did HIMS Retail Traders React?</h2>On Stocktwits, retail sentiment around HIMS stock stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> has fallen 8% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/michael-saylor-says-bitcoin-s-next-bull-run-has-begun-sees-it-back-in-six-figures-within-a-year/cZxq6khRBHT">Michael Saylor Says Bitcoin's Next Bull Run Has Begun, Sees It Back In 'Six Figures' Within A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hims is introducing online weight-management care for men in Germany, beginning with private consultations that can lead to prescriptions from EU-licensed clinicians. 

Hims & Hers Health Inc

iShares Core S&P Mid-Cap ETF

Vanguard Total Stock Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Feed

News

Sentiment

Fundamentals

Info

IJH iShares Core S&P Mid-Cap ETF

Fundamentals

Latest IJH News